Mandy Jackson

@ScripMandy

I am Managing Editor, US Commercial News, for the Informa Pharma Insights publications Scrip and The Pink Sheet. Views expressed here are strictly my own.

San Diego, CA
Vrijeme pridruživanja: svibanj 2012.

Tweetovi

Blokirali ste korisnika/cu @ScripMandy

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ScripMandy

  1. proslijedio/la je Tweet
    4. velj

    We said we'd never do bio. Today, we launched Bio Fund III. Here's why we changed our minds: From a16z Bio general partners:

    Poništi
  2. 4. velj
    Poništi
  3. 3. velj
    Poništi
  4. 31. sij

    A lot of new PR pros started following me during . So, a reminder: & only cover drugs, not medical devices or diagnostics, but our colleagues at would love to receive your device & diagnostic news:

    Poništi
  5. proslijedio/la je Tweet
    31. sij

    Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

    Poništi
  6. 31. sij

    “Gilead is working closely with global health authorities to respond to the novel coronavirus (2019-nCoV) outbreak through the appropriate experimental use of our investigational compound remdesivir.”

    Poništi
  7. 31. sij

    Reyvow and Ubrelvy both have launched. Allergan confirmed that its acute drug is available in pharmacies and prescriptions are being filled.

    Poništi
  8. proslijedio/la je Tweet
    31. sij

    Arcutis Biotherapeutics prices upsized IPO at $17 high end

    Poništi
  9. proslijedio/la je Tweet
    30. sij

    Oncology biotech Black Diamond Therapeutics pops 108% on IPO

    Poništi
  10. 31. sij

    “A benefit of ditans, like Lilly’s Reyvow, is that they are not associated with vasoconstriction, which is seen with triptans, making the older drugs contraindicated in patients with cardiovascular disease.” (Subscription required)

    Prikaži ovu nit
    Poništi
  11. 31. sij

    Reyvow list price for the on-demand migraine treatment is $640 for a package of 8 tablets (on par with $85/dose for CGRP Ubrelvy).

    Prikaži ovu nit
    Poništi
  12. 31. sij

    Is launching its acute migraine drug Reyvow (lasmiditan) now that it has received DEA scheduling - class V, the lowest potential for abuse.

    Prikaži ovu nit
    Poništi
  13. 30. sij

    Murdo Gordon: Over 92% of commercial lives have access to migraine prevention drug Aimovig with affordable co-pay. More than 80% of prescriptions are paid. Reduction in net selling price in Q1 due to new CVS deal, but stabilizing the rest of the year.

    Poništi
  14. 30. sij

    David Reese pipeline updates in line w/those in this story based on my chat w/the EVP of R&D at about Amgen's efforts to work more efficiently, including through use of genomics, proteomics and transcriptomics (subscription reqd).

    Poništi
  15. 30. sij

    All four executives to present - CEO, CFO, EVP commercial and now EVP R&D David Reese - have expressed the company's "enthusiasm for the collaboration with BeiGene"

    Prikaži ovu nit
    Poništi
  16. 30. sij

    Commercial EVP Murdo Gordon notes that Amgen will increase its focus on the psoriasis market now that its has two branded products in this market – Otezla and Enbrel, plus biosimilars.

    Poništi
  17. 30. sij

    CFO Peter Griffith: Net 5% price decline globally in 2019, expect low to mid single-digit net price decline in 2020, which will be more than offset by increased revenue.

    Poništi
  18. 30. sij

    CEO Bob Bradway continues to note, as he did at , that Asia-Pacific will be a major source of growth. Company sees it growing to 25% of its revenue.

    Prikaži ovu nit
    Poništi
  19. 30. sij

    Meanwhile, Q4 revenue of $6.2bn beat consensus of $6.02bn, so perhaps Amgen is aiming low and will beat its guidance significantly by the end of 2020. Beat-and-raise strategy could pay off ...

    Prikaži ovu nit
    Poništi
  20. proslijedio/la je Tweet
    30. sij

    First episode of the year for the Informa Pharma Intelligence Podcast, covering . Listen in as and share their key takeaways from the meeting:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·